Peptide Library
Clear starting points for understanding what a compound is, what people report, what evidence exists, and what remains unknown.
5-Amino-1MQ
Small-molecule NNMT inhibitor — not a peptide; preclinical framing only.
ACE-031
ActRIIB–IgG1 Fc fusion — development discontinued; no monomer CID; refuse PE glow.
ACTH 1-39
Full-length corticotropin (1–39) — labeled RCI/Acthar carefully; ≠ cosyntropin 1–24; ≠ gray-market.
Adamax
Trade-name identity TBD — no CID; Semax-context PMIDs only; ≠ Semax ≠ Selank; AdaMax ML collision.
Adipotide
Prohibitin-targeting FTPP — monkey/mouse only; refuse human fat-loss glow.
AHK-Cu
Ala-His-Lys copper complex — ≠ GHK-Cu; thin evidence pack.
AICAR
Acadesine (AICA-riboside) — ≠ ZMP; mouse exercise-mimetic ≠ human fitness claim.
AOD-9604
Modified fragment of human growth hormone studied in relation to fat metabolism.
ARA-290
Cibinetide (non-erythropoietic EPO helix-B peptide) — ≠ EPO; exploratory SFN/DME pilots.
B7-33
Single-chain relaxin-2 mimetic (RXFP1) — preclinical only; refuse human cardio glow.
BPC-157
Synthetic peptide modeled on a fragment associated with gastric proteins.
Bremelanotide (PT-141)
Melanocortin receptor agonist.
Cagrilintide
Long-acting amylin analogue (AM833) — investigational monotherapy; CagriSema combo is a separate object.
Cardiogen
AEDR ultrashort peptide — never badge L-carnitine CID 10917; ≠ Cartalax AED.
Cartalax
AED ultrashort peptide (CID 87815447) — ≠ Cardiogen AEDR; thin Khavinson set.
Cerebrolysin
Porcine brain hydrolysate — no CID; Cochrane stroke caution visible.
CJC-1295
Long-acting growth-hormone-releasing hormone analog studied for effects on growth hormone signaling.
CJC-1295 with DAC
Long-acting albumin-binding GHRH(1-29) analog with DAC — investigational; not FDA-approved.
CJC-1295 without DAC (Mod GRF 1-29)
Tetrasubstituted GHRH(1-29) amide without DAC (Mod GRF 1-29) — investigational; not FDA-approved.
Dihexa
AngIV analogue / HGF mimetic (PNB-0408) — preclinical only; refuse nootropic glow.
DSIP
Emideltide nonapeptide — older sleep lit; unresolved physiology; no modern approved insomnia claim.
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity-class) — labeled for type 2 diabetes including CV-risk framing.
Eloralintide
Selective long-acting amylin receptor agonist (LY3841136) — investigational obesity candidate.
Epitalon
Synthetic tetrapeptide promoted in longevity communities.
EPO
Labeled ESA biologics (epoetin/darbepoetin class) — anemia labels; Besarab/CHOIR/CREATE/TREAT harm visible; ≠ ARA-290.
FOXO4
Forkhead box O4 transcription factor — ≠ FOXO4-DRI senolytic peptide.
FOXO4-DRI
D-retro-inverso FOXO4–p53 senolytic peptide — preclinical; PH caution; ≠ endogenous FOXO4.
Frag 17-23
Tβ4 residues 17–23 (LKKTETQ / Ac-LKKTETQ) — ≠ hGH Frag 176-191 ≠ thymosin α1.
FST 344
Follistatin FS344 coding isoform — FS344 ≠ FS288 ≠ FS315; AAV gene therapy ≠ black-market protein.
GDF-8
Endogenous myostatin (GDF-8) pathway object — inhibitor drugs ≠ administering myostatin; no PE glow.
GHK-Cu
Naturally occurring copper-binding tripeptide studied in skin and tissue biology.
GHRP-2 (pralmorelin)
GHS-R agonist hexapeptide (pralmorelin / KP-102) — investigational; not FDA-approved.
GHRP-6
Classic Bowers GH-releasing hexapeptide — investigational; not FDA-approved.
Glutathione
Endogenous tripeptide antioxidant (GSH) — biochemistry ≠ IV cosmetic claim; skin-lightening contested.
Gonadorelin
Native GnRH-I decapeptide — diagnostic / pulsatile HH reproductive-endocrine object; ≠ agonists or kisspeptin.
HCG
Labeled fertility glycoprotein (urinary hCG / choriogonadotropin alfa) — ASIH papers are misuse context, not PE.
Hexarelin
Examorelin GHS-R agonist hexapeptide — investigational; not FDA-approved.
HGH Frag 176-191
C-terminal hGH fragment residues 176–191 — investigational; related ≠ AOD-9604.
HMG
Urinary menotropins (FSH+LH biologic mixture) — labeled ART/infertility object; no athletic framing.
Humanin
Mitochondria-derived 24-aa peptide (MT-RNR2) — ≠ MOTS-c ≠ HNG; no human outcome RCTs here.
IGF DES
Des(1-3)IGF-1 — ≠ LR3 ≠ MGF ≠ PEG-MGF; CID/CAS TBD; rodent potency only.
IGF-1 LR3
Long-Arg3-IGF-I engineered analog — ≠ DES ≠ MGF ≠ PEG-MGF; animal + detection only.
Ipamorelin
Growth hormone secretagogue that acts at the ghrelin receptor.
Kisspeptin-10
KISS1R agonist decapeptide (KP-10) — ≠ KP-54; human LH physiology; no consumer fertility label assumed.
KPV
Short tripeptide fragment related to alpha-melanocyte-stimulating hormone research.
Liraglutide
GLP-1 receptor agonist peptide medicine.
LL-37
Human antimicrobial peptide involved in innate immune responses.
Mazdutide
Dual GLP-1 / glucagon receptor agonist (IBI362 / LY3305677) — China NMPA labeled for weight and T2D; not US/EU FDA-approved.
Melanotan
Bare “Melanotan” is an unresolved umbrella — MT1 ≠ MT2 ≠ bremelanotide; no single CID/CAS badge.
Melanotan 1
Afamelanotide / Melanotan-1 family — Scenesse EPP label ≠ gray MT-I ≠ Melanotan II ≠ bremelanotide.
Melanotan II
Synthetic melanocortin analog promoted online for tanning and other effects.
Melatonin
Endogenous indoleamine chronobiotic — ≠ Melanotan; Circadin PR ≠ all OTC melatonin pathways.
MGF
IGF-1 Ec / MGF E-peptide — ≠ DES ≠ LR3 ≠ PEG-MGF; endogenous expression ≠ vial RCTs.
MK677
NOT A PEPTIDE — oral GHSR agonist ibutamoren (CID 178024 / mesylate 6450830); ≠ GHRPs.
MOTS-c
Mitochondrial-derived peptide studied in metabolic signaling and aging biology.
NAD+
Endogenous cofactor NAD+ — biochemistry ≠ IV NAD+/NADH ≠ oral NR/NMN precursors.
Orexin A
Hypocretin-1 neuropeptide — ≠ OX2R agonists ≠ DORAs; CSF diagnostic ≠ vial therapy.
Orexin B
Hypocretin-2 neuropeptide (OX2-preferring) — investigational; ≠ orexin A ≠ DORA hypnotics.
Oxytocin Acetate
Cyclic nonapeptide — labeled obstetric objects exist; investigational IN social/metabolic uses are a different context.
P210
ApoB-100 peptide 210 vaccine antigen — atherosclerosis immunology; ≠ BCR-ABL p210 leukemia fusion.
PE-22-28
Shortened spadin / TREK-1 blocker class — preclinical antidepressant models; CID TBD.
PEG-MGF
PEGylated MGF E-domain lineage — scarce object-matched lit; ≠ naked MGF ≠ PEGylated IGF-I.
Pinealon
EDR tripeptide (Glu-Asp-Arg) — Khavinson-line; ≠ Epitalon ≠ Vesugen ≠ Prostamax.
PNC-27
p53/HDM-2–penetratin chimeric anticancer peptide — in-vitro oncology; ≠ PNC-28.
Prostamax
KEDP tetrapeptide — thin Khavinson chromatin set; ≠ Vesugen ≠ Pinealon ≠ Epitalon.
PT-10
Identity unresolved — no invented CID/CAS/sequence; ≠ PT-141; TP10 is name-collision context only.
PT-20
Identity unresolved — 0 locked PMIDs; ≠ PT-141 ≠ PT-10; no invented badge.
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist (LY3437943) — investigational; not FDA-approved.
Selank
TKPRPGP tuftsin analogue — ≠ Semax ≠ Adamax; no US FDA anxiety assumption.
Semaglutide
GLP-1 receptor agonist peptide medicine.
Semax
MEHFPGP ACTH(4-10) analogue — CID 9811102; ≠ Adamax ≠ Selank; Russian stroke lit ≠ US FDA approval.
Sermorelin
GHRH(1-29)-NH₂ (sermorelin acetate) — investigational; not FDA-approved.
SNAP-8
Acetyl octapeptide-3 (CID 76283482) — thin cosmetic lit; CAS TBD; ≠ Argireline.
SS-31
Elamipretide (Forzinity) — Barth accelerated approval and MMPOWER-3 miss both stay in view.
Survodutide
Dual glucagon / GLP-1 receptor agonist (BI 456906) — investigational; not FDA-approved.
TB-500 / thymosin-related fragments
Names used online for synthetic products associated with thymosin beta-4 research.
TB500 / Tβ4 Acetate Alignment
Aligns checklist “TB500 (Thymosin B4 Acetate)” to the Ac-LKKTETQ fragment drawer — do not merge full Tβ4.
Tesamorelin
Synthetic analog of growth-hormone-releasing factor.
Thymalin
Thymic polypeptide complex — ≠ thymalfasin ≠ TB-500 ≠ Tβ4.
Thymosin Alpha-1
Acetylated 28-aa thymic peptide (thymalfasin) — ≠ Thymalin ≠ TB-500.
Tirzepatide
Dual GIP and GLP-1 receptor agonist peptide medicine.
Triptorelin Acetate
GnRH agonist (D-Trp6-LHRH) — labeled oncology/endocrine depot objects; salt/depot care.
Vesugen
KED tripeptide (Lys-Glu-Asp) — ≠ Pinealon ≠ Prostamax ≠ Epitalon.
VIP
Vasoactive intestinal peptide — ≠ PACAP; inhaled sarcoid/PH exploratory.